Research Connection Projects

Project type

FP7

Sector

Health

Proposal acronym

Helicovaxor

Call ID

FP7-SME-2012

Overview

Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection. the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine:
- Powerful, safe and multivalent antigens;
- Powerful, safe and multi-acting adjuvants;
- Powerful, modular and flexible oral vaccine delivery system.

This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.

Organisations involved

Sigmoid Pharma Limited

Particular Scienes Ltd - PSCI

ALMAC DIAGNOSTICS LIMITED

Trinity College Dublin

Allied Automation Limited